Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422692 · ClinicalTrials.gov registry record · Phase 1
Socket Preservation: A Clinical and Histological Study
A Phase 1 study, sponsored by University of Kentucky.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT03422692: Completed Phase 1 study, sponsored by University of Kentucky.
NCT03422692 is a Phase 1 study that has completed, run by University of Kentucky. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03422692, a Phase 1 study, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the use of human amnion chorion membrane (BioXclude®) as an exposed barrier in ridge preservation and whether the intentional exposure of this membrane to oral environment will adversely affect ridge healing, dimensions, and bone vitality. This is a randomized clinical study.
Primary Outcome
Mean vital bone formation using histomorphometric analysis
Interventions
- BIOLOGICAL BioXclude amnion-chorion membrane
- BIOLOGICAL Mem-Lok collagenous membrane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-10-01 |
| Est. Completion | 2015-10-01 |
| Phase | Phase 1 |
What the finished NCT03422692 record still lists
NCT03422692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 2 interventions - of which BioXclude amnion-chorion membrane is the first listed.
NCT03422692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03422692 about?
NCT03422692 is a clinical study titled "Socket Preservation: A Clinical and Histological Study". The objective of this study is to investigate the use of human amnion chorion membrane (BioXclude®) as an exposed barrier in ridge preservation and whether the intentional exposure of this membrane to oral environment will adversely affect ridge healing, dimensions, and bone vitality. This is a rand...
What is the current status of trial NCT03422692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2013-10-01. Estimated completion is 2015-10-01.
What interventions are being tested in trial NCT03422692?
The interventions under investigation include: BioXclude amnion-chorion membrane (BIOLOGICAL), Mem-Lok collagenous membrane (BIOLOGICAL).
Who is sponsoring clinical trial NCT03422692?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03422692's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI